Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 15/20 | 1.00 |
| ▸ | THRB | P10828 | 15/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 1.00 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.78 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | ASPH | Q12797 | 1/20 | 0.78 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27434200 | 0.98 | THRA (0.96) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL523521 | 0.95 | THRA (0.91) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL27433569 | 0.93 | THRA (0.86) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL30438758 | 0.93 | THRA (0.86) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL28567789 | 0.91 | THRA (0.84) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL522828 | 0.91 | THRA (0.84) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL522364 | 0.91 | THRA (0.84) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL28971844 | 0.91 | THRA (0.83) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL30438601 | 0.91 | THRA (0.83) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL23507869 | 0.90 | THRA (0.82) | THRATHRBEGLN1BBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | claimed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | claimed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | claimed |
| US-8017625-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-09-13 | — | — | US | claimed |
| EP-1644336-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN INC (US) | 2011-01-19 | — | — | EP | claimed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | claimed |
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | claimed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| US-20060251638-A1 | Cytoprotection through the use of hif hydroxylase inhibitors | FIBROGEN, INC. | 2006-11-09 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| WO-2005007192-A2 | CYTOPROTECTION THROUGH THE USE OF HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| EP-4661861-A1 | USE OF HIF-1A STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-12-17 | — | — | EP | disclosed |
| CN-115838354-B | Thyroid hormone receptor beta agonist compound and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2025-05-13 | — | — | CN | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | THRA 3799/4885THRB 3714/4885EGLN1 863/4885 |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | THRA 3705/4885THRB 2221/4885EGLN1 7/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | THRA 3705/4885THRB 2221/4885EGLN1 7/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | THRA 3533/4885THRB 2405/4885EGLN1 7/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | THRA 3705/4885THRB 2221/4885EGLN1 7/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | THRA 3533/4885THRB 2405/4885EGLN1 7/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | THRA 1089/4885THRB 1815/4885EGLN1 16/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | THRA 822/4885THRB 1449/4885EGLN1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.